Eli Lilly is a US pharmaceutical company. Its drugs for diabetes and obesity such as Mounjaro and Zepbound are in particularly high demand. Other focus areas are cancer, immune diseases and Alzheimer’s; it sells worldwide. As of Oct 11, 2026
As of Oct 11, 2026Fact sheet (from the annual report)Pharmaceutical manufacturers · Indianapolis, USAfull fact sheet
The company researches, develops, manufactures and markets human pharmaceuticals in a single business segment. Manufacturing and distribution run through sites in the United States including Puerto Rico as well as in Europe and Asia. In cardiometabolic health, the group offers insulins, Mounjaro for a certain form of diabetes and a medicine for obesity or overweight with a comorbidity. It markets some diabetes medicines in collaboration with Boehringer Ingelheim. Oncology includes Verzenio and Inluriyo for certain forms of breast cancer, among others. Other therapeutic areas are immunology and neuroscience.
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Gap with volume · Analysis method
The price of LLY is currently in no zone of this method. The check runs daily after the market close.
Whether a price will soon reach a zone, you see from Watcher. Plans and pricing
How the zone is formed
What is this? After strong news, usually earnings, the price opened above the previous day’s high and closed much higher on heavy volume. Such moves often continue for a few more days.
Buy zone: from the start of the gap to the close of the gap day. Stop: just below the low of the gap day. Targets: 3 and 5 ATR (normal daily ranges) above the close of the gap day.
The pattern is valid for at most 15 trading days and expires if the price falls below the stop. This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice
Load chart from TradingView
This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Lilly (Eli) · Sector Health Care · amounts in USD
Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 12, 2026.
In short
Light green: Revenue grew over 5 years (+21.6% per year), at least as fast as the sector median.
Light green: Net income (total) grew over 5 years (+27.2% per year), at least as fast as the sector median; per share +27.6% per year.
Light green: Net margin 31.7%, above the sector median (12.9%).
Light red: Debt much higher than usual in the sector.
Light yellow: Profit in 9 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
−20B020B40B60B80B
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 21.2B USD · Net income 2.7B USD · Net margin 12.9%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 22.9B USD · Net income −204.1M USD · Net margin −0.9%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 24.6B USD · Net income 3.2B USD · Net margin 13.2%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 22.3B USD · Net income 8.3B USD · Net margin 37.3%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 24.5B USD · Net income 6.2B USD · Net margin 25.2%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 28.3B USD · Net income 5.6B USD · Net margin 19.7%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 28.5B USD · Net income 6.2B USD · Net margin 21.9%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 34.1B USD · Net income 5.2B USD · Net margin 15.4%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 45.0B USD · Net income 10.6B USD · Net margin 23.5%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.2B USD · Net income 20.6B USD · Net margin 31.7%
Margin
13%−1%13%37%25%20%22%15%24%32%
RevenueNet incomeNet margin (below)in USD
−10B010B20B30B
Q3/23Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 9.5B USD · Net income −57.4M USD · Net margin −0.6%
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 9.4B USD · Net income 2.2B USD · Net margin 23.4% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 8.8B USD · Net income 2.2B USD · Net margin 25.6%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 11.3B USD · Net income 3.0B USD · Net margin 26.3%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 11.4B USD · Net income 970.3M USD · Net margin 8.5%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 13.5B USD · Net income 4.4B USD · Net margin 32.6% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 12.7B USD · Net income 2.8B USD · Net margin 21.7%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 15.6B USD · Net income 5.7B USD · Net margin 36.4%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 17.6B USD · Net income 5.6B USD · Net margin 31.7%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 19.3B USD · Net income 6.6B USD · Net margin 34.4% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 19.8B USD · Net income 7.4B USD · Net margin 37.4%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 23.0B USD · Net income 7.1B USD · Net margin 30.9%
Margin
−1%23%26%26%8%33%22%36%32%34%37%31%
Earnings per shareUSD per share
−100102030
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share 2.58 USD
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share −0.19 USD
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 3.13 USD
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 8.89 USD
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 6.79 USD
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 6.12 USD
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 6.90 USD
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 5.80 USD
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share 11.71 USD
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 22.95 USD
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share 8.26 USD
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share 7.94 USD
Dividend per sharePayout ratio (below)USD per share
02.004.006.008.00
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Dividend per share 2.05 USD · Payout ratio 79.5%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Dividend per share 2.12 USD · Payout ratio not available
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Dividend per share 2.33 USD · Payout ratio 74.4%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Dividend per share 2.68 USD · Payout ratio 30.1%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Dividend per share 3.07 USD · Payout ratio 45.2%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Dividend per share 3.53 USD · Payout ratio 57.7%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Dividend per share 4.07 USD · Payout ratio 59.0%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Dividend per share 4.69 USD · Payout ratio 80.9%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Dividend per share 5.40 USD · Payout ratio 46.1%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Dividend per share 6.23 USD · Payout ratio 27.1%
Ratio
79%74%30%45%58%59%81%46%27%
Dividend per sharePayout ratio (below)USD per share
01.002.003.004.00
Q3/23Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Dividend per share not available · Payout ratio not available
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Dividend per share 2.43 USD · Payout ratio not available · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Dividend per share not available · Payout ratio not available
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Dividend per share 2.60 USD · Payout ratio 79.3%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Dividend per share not available · Payout ratio not available
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Dividend per share 2.80 USD · Payout ratio not available · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Dividend per share not available · Payout ratio not available
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Dividend per share 3.00 USD · Payout ratio 47.7%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Dividend per share not available · Payout ratio not available
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Dividend per share 3.23 USD · Payout ratio not available · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Dividend per share not available · Payout ratio not available
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Dividend per share 3.46 USD · Payout ratio 43.6%
Ratio
79%48%44%
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.2B USD · Net income 20.6B USD · Net margin 31.7%
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light green: above sector
+21.6%per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 21.6% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light green: above sector
+27.2%per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: +27.6% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 27.2% per year on average – at least as fast as the median company in the sector (+7.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue, 31.67 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 25.2%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light red: much higher
1.41latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? For every 1 USD of equity there is 1.41 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light green: covered
27%Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? Of every 1 USD of earnings per share, 0.27 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light yellow: 1 loss year
9 of 10fiscal years with a profit
What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
65.2B USD
Revenue vs. prior year
+44.7%
Net income (FY)
20.6B USD
Net income vs. prior year
+94.9%
EPS (FY)
22.95 USD
13F funds with a position
3 of 9
Funds vs. prior quarter
+1
Shares held vs. prior quarter
−75.6%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 12, 2026 · Balance sheet Jun 30, 2026 (filed Aug 5, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 31, 2025
65.2B
20.6B
31.7%
22.95
6.23
27%
2024
Dec 31, 2024
45.0B
10.6B
23.5%
11.71
5.40
46%
2023
Dec 31, 2023
34.1B
5.2B
15.4%
5.80
4.69
81%
2022
Dec 31, 2022
28.5B
6.2B
21.9%
6.90
4.07
59%
2021
Dec 31, 2021
28.3B
5.6B
19.7%
6.12
3.53
58%
2020
Dec 31, 2020
24.5B
6.2B
25.2%
6.79
3.07
45%
2019
Dec 31, 2019
22.3B
8.3B
37.3%
8.89
2.68
30%
2018
Dec 31, 2018
24.6B
3.2B
13.2%
3.13
2.33
74%
2017
Dec 31, 2017
22.9B
−204.1M
−0.9%
−0.19
2.12
–
2016
Dec 31, 2016
21.2B
2.7B
12.9%
2.58
2.05
79%
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q2/26
Jun 30, 2026
23.0B
7.1B
30.9%
7.94
3.46
44%
Q1/26
Mar 31, 2026
19.8B
7.4B
37.4%
8.26
–
–
Q4/25*
Dec 31, 2025
19.3B
6.6B
34.4%
–
3.23
–
Q3/25
Sep 30, 2025
17.6B
5.6B
31.7%
6.21
–
–
Q2/25
Jun 30, 2025
15.6B
5.7B
36.4%
6.29
3.00
48%
Q1/25
Mar 31, 2025
12.7B
2.8B
21.7%
3.06
–
–
Q4/24*
Dec 31, 2024
13.5B
4.4B
32.6%
–
2.80
–
Q3/24
Sep 30, 2024
11.4B
970.3M
8.5%
1.07
–
–
Q2/24
Jun 30, 2024
11.3B
3.0B
26.3%
3.28
2.60
79%
Q1/24
Mar 31, 2024
8.8B
2.2B
25.6%
2.48
–
–
Q4/23*
Dec 31, 2023
9.4B
2.2B
23.4%
–
2.43
–
Q3/23
Sep 30, 2023
9.5B
−57.4M
−0.6%
−0.06
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +80
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+0
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)32.3
Rel. strength 60 d+13.2%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.